Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Schmouder

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Pharmacology|November 11, 2011
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteersRobert Schmouder, Sam Hariry, Olivier J David
Clinical Drug Investigation|February 23, 2017
Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?Christiane Michel, Emil Scosyrev, Michael Petrin, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate AsthmaCraig Boulton, Olivier J David, Karin Meiser, et al.
Journal of Clinical Pharmacology|December 17, 2011
Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose studyCraig Boulton, Karin Meiser, Olivier J David, et al.
British Journal of Clinical Pharmacology|April 20, 2004
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjectsJohn M Kovarik, Robert Schmouder, Denise Barilla, et al.
Nature Biotechnology|May 12, 2010
Next-generation biomarkers for detecting kidney toxicityJoseph V Bonventre, Vishal S Vaidya, Robert Schmouder, et al.
Clinical Transplantation|July 9, 2002
Administration diluents differentiate Neoral from a generic cyclosporine oral solutionJohn M Kovarik, Denise Barilla, Louis McMahon, et al.
British Journal of Pharmacology|February 17, 2026
Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteersIrina Baltcheva, Guido Junge, Kenneth Kulmatycki, et al.
Journal of Clinical Pharmacology|April 23, 2004
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjectsJohn M Kovarik, Robert Schmouder, Denise Barilla, et al.
Clinical Pharmacology in Drug Development|April 26, 2018
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy SubjectsOlivier J David, Rhett Behrje, Parasar Pal, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Pharmacology|November 11, 2011
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteersRobert Schmouder, Sam Hariry, Olivier J David
Clinical Drug Investigation|February 23, 2017
Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?Christiane Michel, Emil Scosyrev, Michael Petrin, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate AsthmaCraig Boulton, Olivier J David, Karin Meiser, et al.
Journal of Clinical Pharmacology|December 17, 2011
Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose studyCraig Boulton, Karin Meiser, Olivier J David, et al.
British Journal of Clinical Pharmacology|April 20, 2004
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjectsJohn M Kovarik, Robert Schmouder, Denise Barilla, et al.
Nature Biotechnology|May 12, 2010
Next-generation biomarkers for detecting kidney toxicityJoseph V Bonventre, Vishal S Vaidya, Robert Schmouder, et al.
Clinical Transplantation|July 9, 2002
Administration diluents differentiate Neoral from a generic cyclosporine oral solutionJohn M Kovarik, Denise Barilla, Louis McMahon, et al.
British Journal of Pharmacology|February 17, 2026
Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteersIrina Baltcheva, Guido Junge, Kenneth Kulmatycki, et al.
Journal of Clinical Pharmacology|April 23, 2004
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjectsJohn M Kovarik, Robert Schmouder, Denise Barilla, et al.
Clinical Pharmacology in Drug Development|April 26, 2018
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy SubjectsOlivier J David, Rhett Behrje, Parasar Pal, et al.
Pageof 3